Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Tirzepatide, available as Mounjaro ... Studies have already suggested there may be a link between Mounjaro and an increased ...

CHICAGO — ­New clinical trial results on the diabetes and obesity drug tirzepatide have doctors buzzing about its potential to treat heart failure, keep weight off and prevent type 2 diabetes.

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Warning it is ‘not a magic bullet’, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, said: ‘Weight ...

Weight loss jab tirzepatide – commonly sold under the brand name Mounjaro – is set to become available via the NHS for ...

Tirzepatide is commercialized for adults with obesity or with overweight who also have weight-related medical problems as Zepbound in the U.S. and Mounjaro ® in some global markets outside ...

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy ...

Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.